



Studies Presented at NCC Can Reinforce Prescriber Confidence in DOT™ Spectacle Lenses for Myopia Control

Scientific Posters from SightGlass Vision Explore Efficacy with Contrast Management Across Diverse Populations, Lack of Relationship with Astigmatism

DALLAS, March 6, 2026—[SightGlass Vision](#) is presenting findings from two scientific studies on March 9 at the [2026 Netherlands Contact Lens Congress \(NCC\)](#) to further reinforce prescriber confidence in its DOT™ spectacle lenses. Both focus on the power of contrast management for slowing myopia progression in children; one explores efficacy across diverse populations and the other investigates its relationship to astigmatism.

“Our contributions to this year’s NCC program add to the substantial body of evidence surrounding our innovative DOT spectacle lenses,” said Andrew Sedgwick, CEO of SightGlass Vision. “More than 1.5 million children have already worn these lenses worldwide, and we are committed to helping eye care professionals understand their immense potential through rigorous clinical science and experience.^[1]”

[Efficacy of Contrast Management Spectacle Lenses in North American and Chinese Children \(Carta F, et al\)](#) analyzed 12-month data sets from two long-term, multicenter randomized controlled clinical trials. Despite the diverse participant ethnicity (North America: 75% Caucasian, 20% Black; China: 100% Chinese), both axial length (AL) progression and cycloplegic Spherical Equivalent Refraction (cSER) progression were significantly slower in children who wore DOT lenses compared to the control groups. The study was conducted in partnership with Indiana University.

[Relationship Between Contrast Management Spectacle Lenses for Myopia Control and Refractive Astigmatism \(Webley D, et al\)](#) explored if potential links between peripheral defocus spectacle lenses and increased astigmatism could extend to contrast management.^[2] Investigators evaluated right eye refractive data from two long-term, multicenter clinical trials of DOT spectacle lenses in

North America and China, noting astigmatism (>0.25DC) at baseline and 12 months. No significant change in astigmatism between the test and control groups infers that practitioners can prescribe DOT lenses with minimal concern of inducing this undesirable effect. The work was conducted with Aston University.

NCC takes place from March 8-9 at the NH Conference Centre Koningshof in Veldhoven, Netherlands, attracting clinicians, researchers, educators, and developers from across the ocular science and eye care spectrum.

DOT lenses are the first myopia management treatment specifically designed to reduce retinal contrast signalling through the incorporation of light scattering elements.^[3] Children are spending more time indoors, studying, reading, and playing in modern, artificial environments, which may be linked to accelerated myopia progression.^{[4][5][6][7][8]} The lenses mimic more natural contrast to counteract this.^{[9],[10]} They have made their commercial debut in Canada, China, Israel, Spain, and the U.K. *

Founded in 2016, SightGlass Vision now operates as a joint venture of CooperVision, Inc. and Essilor International. For more information, visit [SightGlassVision.com](https://www.SightGlassVision.com).

###

About SightGlass Vision

SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light-scattering elements designed to mimic more natural contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperVision, Inc. and Essilor International to accelerate commercialization opportunities and expand the myopia management category worldwide.

Diffusion Optics Technology and DOT are trademarks of SightGlass Vision, Inc. © 2026 SightGlass Vision, Inc. All Rights Reserved.

* SightGlass Vision™ products are not available for sale in the United States.

Media Contact

Carson Daniels, Senior Counselor

McDougall Communications for SightGlass Vision

+1-315-427-6394 or carson@mcdougallpr.com

^[1] SGV data on file 2025: 2024/25 sales data and repeat purchase rates; reflects global usage across multiple regions.

^[2] Xu et al. The Peripheral Defocus Designed Spectacle Lenses Might Increase Astigmatism in Myopic Children. *Translational Vision Science and Technology* 2025 14:3:8:2

^[3] Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). *Br J Ophthalmol.* 2023;107(11):1709–1715.

^[4] Morgan IG, Wu PC, Ostrin LA, Tideman JWL, Yam JC, Lan W, Baraas RC, He X, Sankaridurg P, Saw SM, French AN, Rose KA, Guggenheim JA. IMI Risk Factors for Myopia. *Invest Ophthalmol Vis Sci.* 2021 Apr 28;62(5):3. doi: 10.1167/iovs.62.5.3. PMID: 33909035; PMCID: PMC8083079.

^[5] Biswas S, El Kareh A, Qureshi M, Lee DMX, Sun CH, Lam JSH, Saw SM, Najjar RP. The influence of the environment and lifestyle on myopia. *J Physiol Anthropol* 2024;43(1):7.

^[6] Flitcroft et al. The Spatial Frequency Content of Urban and Indoor Environments as a Potential Risk Factor for Myopia Development. *Invest. Ophthalmol. Vis. Sci.* 2020;61(11):42

^[7] Guo Y, Liu LJ, Tang P, Lv YY, Feng Y, et al. (2017) Outdoor activity and myopia progression in 4-year follow-up of Chinese primary school children: The Beijing Children Eye Study. *PLOS ONE* 12(4): e0175921

^[8] Li X, Li L, Qin W, et al. Urban Living Environment and Myopia in Children. *JAMA Netw Open.* 2023;6(12):e2346999. doi:10.1001/jamanetworkopen.2023.46999

^[9] Laughton D, et al. Control of myopia using diffusion optics spectacle lenses: 4-year results of a multicentre randomised controlled, efficacy and safety study (CYPRESS): *BMJ Open Ophthalmology* 2024;9:e001790;

^[10] Laughton et al. Control of myopia using contrast modulation spectacle lenses in a Chinese population: 12-month results. *Invest. Ophthalmol. Vis. Sci.* 2025;66(8):2815.